Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Emepronium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Emepronium. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Emepronium. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Emepronium. |
| Hydrocodone | Emepronium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Emepronium. |
| Magnesium sulfate | The therapeutic efficacy of Emepronium can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Emepronium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Emepronium may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Emepronium. |
| Mirtazapine | Emepronium may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Emepronium. |
| Orphenadrine | Emepronium may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Emepronium may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Emepronium. |
| Pramipexole | Emepronium may increase the sedative activities of Pramipexole. |
| Ropinirole | Emepronium may increase the sedative activities of Ropinirole. |
| Rotigotine | Emepronium may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Emepronium. |
| Suvorexant | Emepronium may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Emepronium. |
| Thalidomide | Emepronium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Emepronium may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Aclidinium | The risk or severity of adverse effects can be increased when Emepronium is combined with Aclidinium. |
| Mianserin | Mianserin may increase the anticholinergic activities of Emepronium. |
| Mirabegron | The risk or severity of urinary retention can be increased when Emepronium is combined with Mirabegron. |
| Potassium chloride | The risk or severity of gastrointestinal ulceration can be increased when Emepronium is combined with Potassium chloride. |
| Pramlintide | The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Emepronium. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Emepronium. |
| Tiotropium | The risk or severity of adverse effects can be increased when Emepronium is combined with Tiotropium. |
| Topiramate | The risk or severity of hyperthermia and oligohydrosis can be increased when Emepronium is combined with Topiramate. |
| Umeclidinium | The risk or severity of adverse effects can be increased when Emepronium is combined with Umeclidinium. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Emepronium. |
| Sodium oxybate | Emepronium may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Glycopyrronium | The risk or severity of adverse effects can be increased when Emepronium is combined with Glycopyrronium. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Emepronium is combined with Botulinum toxin type A. |
| Glucagon | Emepronium may increase the gastrointestinal motility reducing activities of Glucagon. |
| Sulpiride | Emepronium may increase the anticholinergic activities of Sulpiride. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Emepronium is combined with Botulinum toxin type B. |
| Eluxadoline | The risk or severity of constipation can be increased when Emepronium is combined with Eluxadoline. |
| Ramosetron | The risk or severity of constipation can be increased when Emepronium is combined with Ramosetron. |
| Ethanol | Emepronium may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Emepronium may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Emepronium. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Emepronium is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Emepronium is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Emepronium is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Emepronium is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Emepronium is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Emepronium is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Emepronium is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Emepronium is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Emepronium is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Emepronium is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Emepronium is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Emepronium is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Emepronium is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Emepronium is combined with Seproxetine. |
| Levomilnacipran | The risk or severity of Tachycardia can be increased when Levomilnacipran is combined with Emepronium. |
| Indalpine | The risk or severity of adverse effects can be increased when Emepronium is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Emepronium is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Emepronium is combined with Alaproclate. |
| Naltrexone | The risk or severity of adverse effects can be increased when Emepronium is combined with Naltrexone. |
| Bezitramide | The risk or severity of adverse effects can be increased when Emepronium is combined with Bezitramide. |
| Desomorphine | The risk or severity of adverse effects can be increased when Emepronium is combined with Desomorphine. |
| Nicomorphine | The risk or severity of adverse effects can be increased when Emepronium is combined with Nicomorphine. |
| Morphine | The risk or severity of adverse effects can be increased when Emepronium is combined with Morphine. |
| Codeine | The risk or severity of adverse effects can be increased when Emepronium is combined with Codeine. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Emepronium is combined with Hydromorphone. |
| Meperidine | The risk or severity of adverse effects can be increased when Emepronium is combined with Meperidine. |
| Oxycodone | The risk or severity of adverse effects can be increased when Emepronium is combined with Oxycodone. |
| Butorphanol | The risk or severity of adverse effects can be increased when Emepronium is combined with Butorphanol. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Emepronium is combined with Dextropropoxyphene. |
| Pentazocine | The risk or severity of adverse effects can be increased when Emepronium is combined with Pentazocine. |
| Sufentanil | The risk or severity of adverse effects can be increased when Emepronium is combined with Sufentanil. |
| Alfentanil | The risk or severity of adverse effects can be increased when Emepronium is combined with Alfentanil. |
| Fentanyl | The risk or severity of adverse effects can be increased when Emepronium is combined with Fentanyl. |
| Nalbuphine | The risk or severity of adverse effects can be increased when Emepronium is combined with Nalbuphine. |
| Levorphanol | The risk or severity of adverse effects can be increased when Emepronium is combined with Levorphanol. |
| Remifentanil | The risk or severity of adverse effects can be increased when Emepronium is combined with Remifentanil. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Emepronium is combined with Diphenoxylate. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Emepronium is combined with Oxymorphone. |
| Dezocine | The risk or severity of adverse effects can be increased when Emepronium is combined with Dezocine. |
| Levacetylmethadol | The risk or severity of adverse effects can be increased when Emepronium is combined with Levacetylmethadol. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Emepronium is combined with Methadyl acetate. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Emepronium is combined with Dihydroetorphine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Emepronium is combined with Diamorphine. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Emepronium is combined with Ethylmorphine. |
| Etorphine | The risk or severity of adverse effects can be increased when Emepronium is combined with Etorphine. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Emepronium is combined with Dextromoramide. |
| Carfentanil | The risk or severity of adverse effects can be increased when Emepronium is combined with Carfentanil. |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Emepronium is combined with Dihydrocodeine. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Emepronium is combined with Alphacetylmethadol. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Emepronium is combined with Dihydromorphine. |
| Ketobemidone | The risk or severity of adverse effects can be increased when Emepronium is combined with Ketobemidone. |
| DPDPE | The risk or severity of adverse effects can be increased when Emepronium is combined with DPDPE. |
| Lofentanil | The risk or severity of adverse effects can be increased when Emepronium is combined with Lofentanil. |
| Opium | The risk or severity of adverse effects can be increased when Emepronium is combined with Opium. |
| Normethadone | The risk or severity of adverse effects can be increased when Emepronium is combined with Normethadone. |
| Piritramide | The risk or severity of adverse effects can be increased when Emepronium is combined with Piritramide. |